PMID- 30112336
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220318
IS  - 2278-330X (Print)
IS  - 2278-4306 (Electronic)
IS  - 2278-330X (Linking)
VI  - 7
IP  - 3
DP  - 2018 Jul-Sep
TI  - Efficacy and safety of nimotuzumab in unresectable, recurrent, and/or metastatic 
      squamous cell carcinoma of the head and neck: A hospital-based retrospective 
      evidence.
PG  - 188-192
LID - 10.4103/sajc.sajc_87_18 [doi]
AB  - CONTEXT: Role of nimotuzumab in locally advanced head and neck cancer (HNC) is 
      well established in India; however, no clinical evidence is available for its 
      role in recurrent and/or metastatic HNC. AIMS: The aim of this study is to 
      evaluate the efficacy and safety of nimotuzumab when added to standard treatment 
      in unresectable, recurrent, and metastatic squamous cell carcinoma of the head 
      and neck (SCCHN). SETTINGS AND DESIGN: Hospital records of 14 patients diagnosed 
      with recurrent and/or metastatic HNC with histologically confirmed squamous cell 
      carcinoma and being treated with nimotuzumab along with standard treatments from 
      December 2010 to December 2016 were retrospectively evaluated. SUBJECTS AND 
      METHODS: The tumor response rate and overall survival (OS) were analyzed. 
      Toxicity and adverse events (AEs) were assessed as per common terminology 
      criteria for adverse events (CTCAE) v 4. RESULTS: Oral cavity was most commonly 
      involved region followed by hypopharynx and oropharynx. At 24 weeks after 
      completion of treatment, overall response rate (complete response (CR) + partial 
      response (PR)) was 75%. Survival rate at 1, 2, and 3 years was 77.80%, 64.81%, 
      and 64.81%, respectively. At a median follow-up of 15.17 months, median OS was 
      not reached. All AEs were either Grade I (66.7%) or Grade II (33.3%). No Grade 
      III or Grade IV AEs were observed. No added toxicity was observed due to 
      nimotuzumab. CONCLUSIONS: In the first of its kind study, the addition of 
      nimotuzumab to standard treatment showed promising response rate as well as 
      survival outcomes in recurrent and/or metastatic SCCHN patients without producing 
      additional toxicity.
FAU - Subramanian, Sundaram
AU  - Subramanian S
AD  - Department of Medical Oncology, VS Hospital and Cancer Center, Chennai, Tamil 
      Nadu, India.
FAU - Sridharan, Nithya
AU  - Sridharan N
AD  - Department of Medical Oncology, VS Hospital and Cancer Center, Chennai, Tamil 
      Nadu, India.
FAU - Balasundaram, V
AU  - Balasundaram V
AD  - Department of Radiation Oncology, VS Hospital and Cancer Center, Chennai, Tamil 
      Nadu, India.
FAU - Chaudhari, Sameer
AU  - Chaudhari S
AD  - Medical affairs, Biocon Ltd, Bengaluru, Karnataka, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - South Asian J Cancer
JT  - South Asian journal of cancer
JID - 101618774
PMC - PMC6069342
OTO - NOTNLM
OT  - Antibodies
OT  - carcinoma
OT  - head and neck neoplasms
OT  - inoperable
OT  - metastatic
OT  - monoclonal
OT  - nimotuzumab
OT  - overall survival
OT  - recurrent
OT  - squamous cell
OT  - therapy
OT  - tumor response
COIS- There are no conflicts of interest.
EDAT- 2018/08/17 06:00
MHDA- 2018/08/17 06:01
PMCR- 2018/07/01
CRDT- 2018/08/17 06:00
PHST- 2018/08/17 06:00 [entrez]
PHST- 2018/08/17 06:00 [pubmed]
PHST- 2018/08/17 06:01 [medline]
PHST- 2018/07/01 00:00 [pmc-release]
AID - SAJC-7-188 [pii]
AID - 10.4103/sajc.sajc_87_18 [doi]
PST - ppublish
SO  - South Asian J Cancer. 2018 Jul-Sep;7(3):188-192. doi: 10.4103/sajc.sajc_87_18.